Screener
Immunovant, Inc. IMVT EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | Years Ended March 31, 2026 | Years Ended March 31, 2025 | Years Ended March 31, 2024 |
|---|---|---|---|
| Total operating expenses | 532,902 | 438,152 | 282,709 |
| Interest income, net | (25,330) | (24,732) | (24,948) |
| Other (income) expense, net | (2,181) | (471) | 1,008 |
| Loss before provision for income taxes | (505,391) | (412,949) | (258,769) |
| Provision for income taxes | 215 | 891 | 567 |
| Net loss | $(505,606) | $(413,840) | $(259,336) |
| Net loss per common share — basic and diluted | $(2.77) | $(2.73) | $(1.88) |
| Weighted average common shares outstanding — basic and diluted | 182,421,233 | 151,573,553 | 138,100,577 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s EPS (basic)?
- Immunovant, Inc. (IMVT) reported EPS (basic) of -$0.73 in Q1 2026.
- How has Immunovant, Inc.'s EPS (basic) changed year-over-year?
- Immunovant, Inc.'s EPS (basic) decreased by 15.9% year-over-year, from -$0.63 to -$0.73.
- What is the long-term trend for Immunovant, Inc.'s EPS (basic)?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s EPS (basic) has grown at a 18.1% compound annual growth rate (CAGR), from -$1.43 to -$2.78.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about Immunovant, Inc.'s eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude